News | Published:

Dye dispute leans Amersham's way

Nature volume 409, page 121 (11 January 2001) | Download Citation

Subjects

Rival manufacturers of automated DNA-sequencing machines have clashed in a California courtroom over the intellectual property rights to the fluorescent dye used in their equipment.

According to a pretrial ruling made last week by US federal judge Charles Breyer, the dye technology used by the California-based Applied Biosystems infringes a patent held by the British company Amersham Pharmacia Biotech. The case will come to full trial later this month.

The ruling is one of several in a tit-for-tat battle over various patents and claims on sequencing technology, which began when Amersham sued Applied Biosystems in 1997 over the launch of its BigDye product.

At stake are not only the market shares of Applied Biosystem's 3700 Prism DNA analyser and Amersham's MegaBACE system, but also a slice of the glory for the sequencing of the human genome.

In a written statement in response to the pretrial ruling, Applied Biosystems said that the company “continues to believe that we will prevail”. But Sir William Castell, chairman of Amersham, describes the ruling as “very significant”. He adds that the onus is now be on Applied Biosystems to invalidate the pretrial ruling.

Amersham is suing Applied Biosystems for undisclosed financial damages. The trial is expected to end in February, with a 90-day period for appeals.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/35051755

Authors

  1. Search for Declan Butler in:

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing